Beyond Avoidance: IgE-Mediated Food Allergies " Therapeutic Innovations to the Rescue

In the United States, food-induced allergic reactions are the leading cause of anaphylaxis in hospital emergency departments. Among these, immunoglobulin E (IgE)-mediated food allergies are the most common, and they pose significant risks, including cardiac arrest and respiratory failure. Traditionally, treatment options for IgE-mediated food allergies have been primarily limited to food avoidance and anaphylaxis prevention. However, recent years have brought the FDA approval of the first oral immunotherapy agent for peanut allergy in addition to the biologic omalizumab for IgE-mediated food allergies. This educational program, developed in collaboration with Food Allergy Research & Education (FARE), aims to provide family medicine physicians and other healthcare professionals with the latest insights into managing IgE-mediated food allergies. The panel of distinguished experts will explore the pathophysiological underpinnings of IgE-mediated food allergies, assess the efficacy and safety of traditional and emerging treatments, and discuss the latest guidelines for managing these conditions. The panel will also highlight the importance of shared decision-making and interdisciplinary approaches to optimize patient care.